1. INVESTOR UPDATE
PERFORMANCE REVIEW: Q3FY13

2. Presentation Path Aarti Industries – Profile Core Strengths
Segmental overview
Q3 FY13 Segmental Performance
Condensed Statement of Operations
Segmental Revenue Growth Trend
Q3 FY13 Financial Highlights
Financial Highlights – over 6 quarters
Financial Highlights – Graphical Highlights
Key Developments – Q3 FY13
New Investment Plans
Annexure / Back-up slides – Financial Statements

3. Aarti Industries - Profile
Leading manufacturer of Speciality Chemicals & Pharmaceuticals with diversified end-uses in Pharmaceuticals, Agrochemicals, Polymer, Additives, Surfactants, Pigments, Dyes, etc.
Promoters are First Generation Technocrats with sound entrepreneurial Skills.
Manufacturing units of Global Scale & Size and are situated in the State of Gujarat, Maharashtra, Madhya Pradesh and U.T. of Silvassa.
Highly integrated Plants with Cost-Efficient Manufacturing Process,.
Pioneer to introduce latest technology and manufacturing processes in India with the help of World Class R & D
Globally ranks at 1st – 5th Position for majority of its key products

4. Core Strengths
Presence in high margin specialty chemicals with diverse applications
Global Scale Units
Manufacturing more than 125 products
Ability to Supply Basket of products to Global Customers & MNCs
Tagged as “Strategic Supplier” by various Global MNCs
Backward Integration
Latest Manufacturing Technology & World Class R&D
Superior Cost Management Skills & Economies of Scale
Capability to convert by-products into commercially viable product
IPRs for Developing Customized Products & Products under Secrecy Agreements
Captive Power Plants

5. Product & Process Flexibility
A significant portion of Aarti’s Production capabilities are process driven and not based on a particular product. This gives Aarti the flexibility to change its input mix and manufacture different products, thereby resulting into optimum utilization of production capabilities
Brief Structure of Aarti Industries’ Production Capabilities

6. Segmental overview Performance Home & Personal Care
Polymer & additives
Dyes, Pigments, Paints & Printing Inks
Rubber chemicals, Resins, etc.
Home & Personal Care
Non-ionic Surfactants
Concentrates for shampoo, hand wash & dish wash
Agro-ingredients & Fertilizers
Fertilizer
Nutrients
Agrochemicals & intermediates
Pharmaceuticals
Active Pharmaceutical Ingredients (APIs)
CRAMS

7. Q3 FY13 Segmental Performance (standalone)
In Rs. Lakh
Particulars
Performance
Agro
Pharma
H&PC
Total
Income
27,993
10,154
4,387
3,402
45,936
% of Total Income
60.94%
22.10%
9.55%
7.41%
100.00%
Export
15,349
5,080
1,729
383
22,540
% of Sales
54.83%
50.03%
39.41%
11.26%
49.07%
EBIT
4,062
1,832
164 90
6,148
EBIT Margin
14.51%
18.05%
3.74%
2.63%
13.38%

8. Condensed Statement of Operations (standalone)
In Rs. Lakh
Particulars
Q3FY13
% of Total Income
Q3FY12
Y-o-Y Growth (%)
Income from Operations
44,998
97.96%
40,667
97.29%
10.65%
Other Operating Income
938
2.04%
1,134
2.71%
(17.28%)
Total Income
45,936
100.00%
41,801
9.89%
Exports
22,540
49.07%
19,007
45.47%
18.59%
Operating Expenditure
39,221
85.38%
35,236
84.29%
11.31%
EBITDA
6,715
14.62%
6,565
15.71%
2.28%
Depreciation
1,671
3.64%
1,368
3.27%
22.15%
Other Income 92
0.20% 25
0.06%
268.00%
EBIT
5,136
11.18%
5,222
12.49%
(1.65%)
Finance Cost
2,054
4.47%
1,816
4.34%
13.11%
Profit Before Tax
3,082
6.71%
3,406
8.15%
(9.51%)
Tax Expenses
900
1.96%
1,105
2.64%
(18.55%)
Profit After Tax
2,182
4.75%
2,301
5.50%
(5.17%)

9. Segmental Revenue Growth Trend (standalone)
In Rs. Lakh
Segments Q1
FY12 Q2 Q3 Q4
Annual FY11-12
FY13
Performance Chemicals
26,113
23,371
23,535
23,779
96,798
25,409
28,451
27,993
Agri-Intermediates & Fertilisers
6,047
8,441
10,072
13,670
38,230
10,466
10,384
10,154
Pharmaceuticals
3,565
3,834
4,128
4,935
16,462
4,803
4,284
4,387
Home & Personal Care
3,231
4,251
4,066
4,293
15,841
4,211
3,843
3,402
Total Income
38,956
39,897
41,801
46,677
167,331
44,889
46,962
45,936

10. Financial Highlights – over 7 quarters (standalone)
In Rs. Lakh
Particulars Q1
FY12 Q2 Q3 Q4
Annual FY11-12
FY13
Total Income
38,956
39,897
41,801
46,677
167,331
44,889
46,962
45,936
Exports
16,450
16,484
19,007
20,835
72,776
21,749
23,645
22,540
% of Total Inc.
42.23%
41.32%
45.47%
44.64%
43.49%
48.45%
50.35%
49.07%
EBITDA
5,396
5,357
6,565
7,147
24,465
6,811
7,392
6,715
EBITDA Margin
13.85%
13.43%
15.71%
15.31%
14.62%
15.17%
15.74%
EBIT
4,263
4,094
5,222
5,773
19,352
5,504
5,930
5,136
EBIT Margin
10.94%
10.26%
12.49%
12.37%
11.57%
12.26%
12.63%
11.18%
PAT
1,807
1,787
2,301
2,824
8,719
2,504
2,826
2,182
PAT Margin
4.64%
4.48%
5.50%
6.05%
5.21%
5.58%
6.02%
4.75%
EPS
2.36
2.33
3.00
3.68
11.36
3.16
3.57
2.76

11. EBITDA (Rs. Lakh) & EBITDA as a %
Financial Highlights – Graphical Layout…1 (standalone)
Total Income (Rs. Lakh)
Exports (Rs. Lakh) & Exports as % of Total Income
EBITDA (Rs. Lakh) & EBITDA as a %
Net Profit (Rs. Lakh)

12. Key developments in Q3FY13
The Board of Directors have declared an interim dividend of Rs 1.25, for each equity shares of Rs 5.
This is the second interim dividend declared by the board this fiscal aggregating to a total interim dividend of Rs 2.75 for each equity share of Rs.5.
Commissioning of additional Hydrogenation unit at Jhagadia thereby increasing the production capabilities from 1,500 tpm to 3,000 tpm
Commissioning of backward integrated Hydrogen Gas Generation plant at Jhagadia.
Production of 1,400 tpm of hydrogenated products in Q3FY13.

13. Key developments in Q3FY13
During the quarter, the company had taken a mandatory annual shutdown for maintenance of its Sulphuric Acid plant at Vapi. This had resulted for decline in topline and EBIDTA. EBIDTA from this unit was lower by approx Rs 4 crs in this qtr as compared to previous quarters.
Commissioning of New Additional Hydrogenation Unit and backward integrated Hydrogen Gas Generation Plant in Q3 has resulted the increase in Depreciation and fixed overheads, while the benefits from these new capacities shall start from Q4FY13.

14. New Investments
The Board of Directors, have approved an investment of Rs 35 crore for setting up a 200,000 tpa Single Super Phosphate unit at Jhagadia
This unit shall consume the byproduct (i.e. Dilute Sulphuric Acid) generated at the existing / expanded manufacturing unit of the Company.
The new unit is expected to be commissioned by Q4FY14.

15. Growth Drivers Growth Drivers
Exports led Growth: Growth in exports volume across various developed markets had been a key driver for increased operations.
Flexibility to maximize margins – Interchangeable Production facilities of Performance & Agro-chemicals helps optimise the product mix to fetch better margins.
Pharmaceuticals volume marginally lower due to debottlenecking exercise carried at one of unit. Growth momentum in pharmaceuticals segment to pickup

16. Thank You
For further information please log on to or contact:
Mr. Chetan Gandhi / Mrs. Mona Patel
Tel: +91 (22) ;
Mr. Siddharth Kumar / Mr. Dhiraj Rajpal
Mobile: / /

17. Annexure – Financial Statements

20. Important Disclaimer
AARTI INDUSTRIES LIMITED may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with Bombay Stock Exchange and National Stock Exchange, and our reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the AARTI INDUSTRIES LIMITED.
All information contained in this presentation has been prepared solely by AARTI INDUSTRIES LIMITED. AARTI INDUSTRIES LIMITED does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith.